बोस्निया और हर्ज़ेगोविना - क्रोएशियाई - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

clinres farmacija d.o.o. - ремифентанил - prašak za koncentrat za rastvor za injekciju/infuziju - 1 mg/1 bočica - 1 bočica sa praškom za koncentrat za rastvor za injekciju/infuziju sadrži: 1 mg remifentanil (u obliku remifentanilhidrohlorida)

यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

teva b.v. - telmisartan - hipertenzija - sredstva koja djeluju na sustav renin-angiotenzina - liječenje esencijalne hipertenzije kod odraslih osoba.

क्रोएशिया - क्रोएशियाई - HALMED (Agencija za lijekove i medicinske proizvode)

fresenius kabi d.o.o., radnička cesta 37a, zagreb, hrvatska - propofol - emulzija za injekciju / infuziju - 10 mg/ml - urbroj: 1 ml emulzije sadrži 10 mg propofola

क्रोएशिया - क्रोएशियाई - HALMED (Agencija za lijekove i medicinske proizvode)

fresenius kabi d.o.o., radnička cesta 37a, zagreb, hrvatska - propofol - emulzija za injekciju / infuziju - 20 mg/ml - urbroj: 1 ml emulzije sadrži 20 mg propofola

क्रोएशिया - क्रोएशियाई - HALMED (Agencija za lijekove i medicinske proizvode)

medical intertrade d.o.o., sveta nedelja - spirale koje se implementiraju u intrakranijalne aneurizme i vaskularne malformacije u svrhu obliteracije

बोस्निया और हर्ज़ेगोविना - क्रोएशियाई - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - ceftriakson - prašak za rastvor za injekciju/infuziju - 1 g/1 viala - 1 bočica sa praškom za rastvor za injekciju/infuziju sadrži: 1 g ceftriakson (u obliku ceftriaksondinatrijum, triseskvihidrata)

मोंटेनेग्रो - क्रोएशियाई - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

glaxosmithkline export limited, velika britanija-dsd, podgorica - remifentanil - prašak za koncentrat za rastvor za injekciju/infuziju - 1mg

मोंटेनेग्रो - क्रोएशियाई - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

glaxosmithkline export limited, velika britanija-dsd, podgorica - remifentanil - prašak za koncentrat za rastvor za injekciju/infuziju - 2mg

मोंटेनेग्रो - क्रोएशियाई - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

b. braun adria d.o.o. za proizvodnju, trgovinu i usluge dio stranog druŠtva u crnoj gori podgorica - propofol - emulzija za injekciju/infuziju - 10mg/ml

यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastična sredstva - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq u monoterapiji namijenjen za liječenje odraslih bolesnika s lokalno-uobičajena ili metastatskih НМРЛ nakon što je ranije kemoterapije. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq u monoterapiji namijenjen za liječenje odraslih bolesnika s lokalno-uobičajena ili metastatskih НМРЛ nakon što je ranije kemoterapije. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.